Compass Therapeutics (CMPX) Return on Sales (2024 - 2025)
Compass Therapeutics (CMPX) reported Return on Sales of 0.88% for Q2 2025, down 73.0% on a YoY basis from 3.27% in Q2 2024, and down 38.55% sequentially from 0.64% in Q4 2024.
Compass Therapeutics (CMPX) Return on Sales (2024 - 2025) Analysis & Trends
Compass Therapeutics (CMPX) has 2 years of Return on Sales data on file, last reported at 0.88% in Q2 2025.
- For the quarter ending Q2 2025, Return on Sales fell 73.0% year-over-year to 0.88%; the trailing twelve-month figure through Jun 2025 stood at 0.88% (down 33.0% YoY), and the FY2024 full-year result was 1.36%, changed N/A from the prior year.
- Return on Sales fell to 0.88% in Q2 2025, from 0.64% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.15% in Q2 2024 to a low of 0.88% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -0.88% |
| Dec 31, 2024 | -0.64% |
| Sep 30, 2024 | -0.60% |
| Jun 30, 2024 | -0.15% |